Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma

Dong W. Kim, Kwangzoo Chung, Weon K. Chung, Sun H. Bae, Dong O. Shin, Seongeon Hong, Sung H. Park, Sung Yong Park, Chae Seon Hong, Young K. Lim, Dongho Shin, Se B. Lee, Hyun ho Lee, Jiwon Sung, Myonggeun Yoon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.

Original languageEnglish
Article number109
JournalRadiation Oncology
Volume9
Issue number1
DOIs
Publication statusPublished - 2014 May 8

Fingerprint

Intensity-Modulated Radiotherapy
Hepatocellular Carcinoma
Radiation
Neoplasms
Stomach
Rectum
Lung
Therapeutics
Small Intestine
Prostate
Ovary
Organs at Risk
Liver
Ionizing Radiation
Glass
Thyroid Gland
Incidence

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. / Kim, Dong W.; Chung, Kwangzoo; Chung, Weon K.; Bae, Sun H.; Shin, Dong O.; Hong, Seongeon; Park, Sung H.; Park, Sung Yong; Hong, Chae Seon; Lim, Young K.; Shin, Dongho; Lee, Se B.; Lee, Hyun ho; Sung, Jiwon; Yoon, Myonggeun.

In: Radiation Oncology, Vol. 9, No. 1, 109, 08.05.2014.

Research output: Contribution to journalArticle

Kim, DW, Chung, K, Chung, WK, Bae, SH, Shin, DO, Hong, S, Park, SH, Park, SY, Hong, CS, Lim, YK, Shin, D, Lee, SB, Lee, HH, Sung, J & Yoon, M 2014, 'Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma', Radiation Oncology, vol. 9, no. 1, 109. https://doi.org/10.1186/1748-717X-9-109
Kim, Dong W. ; Chung, Kwangzoo ; Chung, Weon K. ; Bae, Sun H. ; Shin, Dong O. ; Hong, Seongeon ; Park, Sung H. ; Park, Sung Yong ; Hong, Chae Seon ; Lim, Young K. ; Shin, Dongho ; Lee, Se B. ; Lee, Hyun ho ; Sung, Jiwon ; Yoon, Myonggeun. / Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. In: Radiation Oncology. 2014 ; Vol. 9, No. 1.
@article{dbba7d698b1e4e3e9a598ae35b811712,
title = "Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma",
abstract = "Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.",
keywords = "EAR, ERR, HCC, IMRT, LAR, OED, Radiophotoluminescence, Tomotherapy, VMAT",
author = "Kim, {Dong W.} and Kwangzoo Chung and Chung, {Weon K.} and Bae, {Sun H.} and Shin, {Dong O.} and Seongeon Hong and Park, {Sung H.} and Park, {Sung Yong} and Hong, {Chae Seon} and Lim, {Young K.} and Dongho Shin and Lee, {Se B.} and Lee, {Hyun ho} and Jiwon Sung and Myonggeun Yoon",
year = "2014",
month = "5",
day = "8",
doi = "10.1186/1748-717X-9-109",
language = "English",
volume = "9",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma

AU - Kim, Dong W.

AU - Chung, Kwangzoo

AU - Chung, Weon K.

AU - Bae, Sun H.

AU - Shin, Dong O.

AU - Hong, Seongeon

AU - Park, Sung H.

AU - Park, Sung Yong

AU - Hong, Chae Seon

AU - Lim, Young K.

AU - Shin, Dongho

AU - Lee, Se B.

AU - Lee, Hyun ho

AU - Sung, Jiwon

AU - Yoon, Myonggeun

PY - 2014/5/8

Y1 - 2014/5/8

N2 - Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.

AB - Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.

KW - EAR

KW - ERR

KW - HCC

KW - IMRT

KW - LAR

KW - OED

KW - Radiophotoluminescence

KW - Tomotherapy

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=84901246509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901246509&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-9-109

DO - 10.1186/1748-717X-9-109

M3 - Article

C2 - 24886163

AN - SCOPUS:84901246509

VL - 9

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 109

ER -